Discover Alector's latest breakthroughs in neurodegenerative disease therapies, including updates on Alzheimer's and Parkinson's programs.
The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide ...
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, United States ...
Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid ...
Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic cancer ...
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
Silexion Therapeutics Corp. (NASDAQ:SLXN) saw its stock surge 400% after unveiling positive preclinical findings for its ...
Investing.com -- Silexion Therapeutics Corp. (NASDAQ:SLXN) stock soared 400% after the company reported positive preclinical data for its pancreatic cancer drug SIL204, demonstrating the treatment’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback